Trial Profile
A prospective, observational, follow-up study to evaluate the influence of golimumab levels on clinical response in spondyloarthritis patients at 52 Weeks.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2015
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- 17 Jul 2015 New trial record